IS7357A - Notkun bensóþíasepíns með tálmvirkni gegn flutningi gallsýru í dausgörn til að draga úr kólesterólhækkun - Google Patents

Notkun bensóþíasepíns með tálmvirkni gegn flutningi gallsýru í dausgörn til að draga úr kólesterólhækkun

Info

Publication number
IS7357A
IS7357A IS7357A IS7357A IS7357A IS 7357 A IS7357 A IS 7357A IS 7357 A IS7357 A IS 7357A IS 7357 A IS7357 A IS 7357A IS 7357 A IS7357 A IS 7357A
Authority
IS
Iceland
Prior art keywords
benzothiazepine
bile acid
acid transport
reduce cholesterol
cholesterol elevation
Prior art date
Application number
IS7357A
Other languages
English (en)
Inventor
Lindqvist Ann-Margret
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7357A publication Critical patent/IS7357A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS7357A 2002-01-26 2004-07-21 Notkun bensóþíasepíns með tálmvirkni gegn flutningi gallsýru í dausgörn til að draga úr kólesterólhækkun IS7357A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201850.5A GB0201850D0 (en) 2002-01-26 2002-01-26 Therapeutic treatment
PCT/GB2003/000350 WO2003061663A1 (en) 2002-01-26 2003-01-23 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia

Publications (1)

Publication Number Publication Date
IS7357A true IS7357A (is) 2004-07-21

Family

ID=9929835

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7357A IS7357A (is) 2002-01-26 2004-07-21 Notkun bensóþíasepíns með tálmvirkni gegn flutningi gallsýru í dausgörn til að draga úr kólesterólhækkun

Country Status (17)

Country Link
US (1) US20050124557A1 (is)
EP (1) EP1478368A1 (is)
JP (1) JP2005523255A (is)
KR (1) KR20040079949A (is)
CN (1) CN1617729A (is)
BR (1) BR0307093A (is)
CA (1) CA2473721A1 (is)
GB (1) GB0201850D0 (is)
HU (1) HUP0500009A3 (is)
IS (1) IS7357A (is)
MX (1) MXPA04007201A (is)
NO (1) NO20043549L (is)
PL (1) PL371521A1 (is)
RU (1) RU2004126148A (is)
TW (1) TW200302089A (is)
WO (1) WO2003061663A1 (is)
ZA (1) ZA200405866B (is)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PT1427423E (pt) 2001-09-08 2007-03-30 Astrazeneca Ab Derivados de benzotiazepina e benzotiadiazepina com actividade inibidora do transporte ileal de ácidos biliáres (ibat) para o tratamento de hiperlipidemia
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) * 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US9339480B2 (en) * 2008-11-26 2016-05-17 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
EP3777864A1 (en) 2010-11-08 2021-02-17 Albireo AB Ibat inhibitors for the treatment of liver diseases
SG189470A1 (en) * 2010-11-08 2013-05-31 Albireo Ab Ibat inhibitors for treatment of metabolic disorders and related conditions
US20120114588A1 (en) * 2010-11-08 2012-05-10 Albireo Ab Ibat inhibitors for treatment of metabolic disorders and related conditions
WO2012064267A1 (en) * 2010-11-08 2012-05-18 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
DK2771003T3 (en) 2011-10-28 2017-07-17 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
UA126268C2 (uk) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
EA201890096A1 (ru) 2015-06-22 2018-08-31 Арена Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP3810581A1 (en) 2018-06-20 2021-04-28 Albireo AB Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN113677398B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
TW202134220A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
PE20230234A1 (es) 2019-12-04 2023-02-07 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
JP2023504643A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
HUE065571T2 (hu) 2019-12-04 2024-06-28 Albireo Ab Benzotia(di)azepin vegyületek és alkalmazásuk epesav modulátorként
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
KR20230117393A (ko) 2020-12-04 2023-08-08 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US20230338392A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900757A (en) * 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
DK0864582T3 (da) * 1997-03-14 2003-09-29 Aventis Pharma Gmbh Hypolidemiske 1,4-benzothiazepin-1,1-dioxider
SE0000772D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
BR0307093A (pt) 2004-12-28
MXPA04007201A (es) 2004-11-26
HUP0500009A3 (en) 2006-05-29
HUP0500009A2 (hu) 2005-04-28
US20050124557A1 (en) 2005-06-09
GB0201850D0 (en) 2002-03-13
EP1478368A1 (en) 2004-11-24
RU2004126148A (ru) 2005-05-27
NO20043549L (no) 2004-08-25
CA2473721A1 (en) 2003-07-31
KR20040079949A (ko) 2004-09-16
TW200302089A (en) 2003-08-01
WO2003061663A1 (en) 2003-07-31
JP2005523255A (ja) 2005-08-04
CN1617729A (zh) 2005-05-18
ZA200405866B (en) 2006-07-26
PL371521A1 (en) 2005-06-27

Similar Documents

Publication Publication Date Title
IS7357A (is) Notkun bensóþíasepíns með tálmvirkni gegn flutningi gallsýru í dausgörn til að draga úr kólesterólhækkun
LTPA2017004I1 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
ATE411302T1 (de) Thiazolidin-4-ones um hyak3 proteinen zu hemmen
NO20034857D0 (no) Tilknytning til bruk med utvidbare rör
ATE383329T1 (de) Biaryloxymethylarenecarbonsäure
DK1660090T3 (da) Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
FR2908045B1 (fr) Utilisation anti-pelliculaire d&#39;un principe actif riche en tannis hydrolysables
IS8360A (is) Mótlyf styrkthjöppunarhormóns melaníns
PT1781145T (pt) Ferramenta para facilitar o consumo de substâncias ingeríveis
NO20043305D0 (no) Preparation of lodixanol
DE60307556D1 (de) Verbindungsstruktur von Verbindern
DK1575413T3 (da) Dispenser med flere driftsformer
DE60327253D1 (de) Nahrungszusammensetzung enthaltend l(+)-milchsäure
EP1765761A4 (en) NOVEL ANALOGUES OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID
IS7488A (is) Dreyfasamsetning í föstu formi
EP1765149A4 (en) USE OF RELAXIN TO INCREASE ARTERIAL COMPLIANCE
PL381612A1 (pl) Pirydynowe pochodne alkilooksindoli jako aktywne czynniki 5-HT7
ZA200701800B (en) Use of thyroid hormone conversion inhibitors
ATA14002004A (de) Pumpfähiger selbstnivellierender magnesiaestrich
FI20021531A (fi) Muurausmenetelmä
SE0601411L (sv) Förfarande vid beredning
DE602004031534D1 (de) Stabiler polymorph von bifeprunoxmesilat
ITMI20040218A1 (it) Uso di neridronato sodico per promuovere la neoformazione ossea
EE04848B1 (et) Meetod (-)-R-homosidrunhappe- ja (+)-S-homosidrunhappe laktoonide saamiseks
NO20021905D0 (no) Plaster med salveblemme